Neurotech International (ASX: $NTI) Clinical Activities Report

Neurotech International Limited (ASX: $NTI) has released its Quarterly Activities Report for the period ending 30 June 2024, showcasing positive clinical trial results in paediatric neurological disorders. The Company's clinical-stage biopharmaceutical development efforts have demonstrated statistically significant and clinically meaningful improvements in Autism Spectrum Disorder (ASD) and Rett Syndrome patients, as well as continued progress in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS). Neurotech International closed the quarter with cash and cash equivalents of $11.6 million, positioning the company well for future clinical and regulatory initiatives.

Executive Commentary

Professor Michael Fahey, Head of the Paediatric Neurology Unit at Monash Medical Centre and the Chief Investigator of the NTIASD2 Trial, expressed his satisfaction with the clinical trial results, stating, 'The analysis so far of the trial have demonstrated statistically significant and clinically meaningful improvements in the severity of illness and adaptive behaviours such as communication and socialization without any significant side effects. Currently, there are no FDA or TGA-approved treatments that show clinically significant improvements in one or more of autism's three core symptom domains: communication, impaired social interaction, and restricted behaviors. Therefore, the NTIASD2 clinical trial data look promising, given the substantial unmet market need for safe and effective therapies for autism, like NT1164.'

Summary

Neurotech International (ASX: $NTI) has achieved significant milestones in its clinical-stage biopharmaceutical development, demonstrating positive clinical trial results in Autism Spectrum Disorder (ASD) and Rett Syndrome patients. The Company's NT1164 has shown statistically significant and clinically meaningful improvements across multiple measures of assessments relating to severity of illness, adaptive behaviors, and socialization. Furthermore, the establishment of an expert advisory group and strategic partnerships reflect Neurotech's commitment to advancing its therapies for paediatric neurological disorders. With a strong cash position and ongoing clinical and regulatory initiatives, Neurotech is well-positioned to continue its progress and deliver on its future ambitions in the field of paediatric neurological disorders.